Comparing the current results to its competitors, Pepgen Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 14.64 %, recorded in the same quarter.
Pepgen Inc , slower than the average decrease reported by the company's competitors of -48.08 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -48.08 %
Pepgen Inc 's Comment on Competition and Industry Peers
The company faces competition from various entities developing alternative scientific and technological approaches, including conjugates with oligonucleotides for extra-hepatic delivery, gene therapy, and gene editing. Competitors include Rgenta Therapeutics, Alnylam Pharmaceuticals, Inc., Aro Biotherapeutics Co., Arrowhead, Avidity, Dyne, Entrada, Ionis Pharmaceuticals, Inc., PYC Therapeutics Limited, and Sarepta. These competitors often possess greater financial resources and expertise in research and development, manufacturing, preclinical testing, clinical trials, regulatory approvals, and marketing, which may enable them to achieve greater success and potentially render the company's treatments obsolete or non-competitive.
April 12, 2025
for CSIMarket.com : PepGen Inc. s Investor Concerns Amidst Industry Competition On April 12, 2025, Pomerantz LLP initiated an investigation on behalf of investors of PepGen Inc. (NASDAQ: PEPG) following concerning financial results. This investigation underscores the rising anxieties among shareholders regarding the company’s financial health in relation to its competitors in the biopharmaceutical industry. In the fourth quarter of 2024, PepGen Inc. reported a year-on-year revenue decrease of 0%. This figure may initially seem stable, yet it starkly contrasts with an impressive 25.47% increase in revenue experienced by many of its competitors during the same period. This discrepancy raises significant ...
March 30, 2025
In a significant development for shareholders, Pomerantz LLP, a renowned securities law firm, has initiated an investigation into potential claims on behalf of the investors of PepGen Inc (NASDAQ: PEPG). This move comes amidst troubling financial figures presented by the company for the last quarter of 2024, coupled with a performance disparity between PepGen and its industry peers. Pomerantz Probes Deep into PepGenHeadquartered in New York, Pomerantz LLP has a long-standing reputation for protecting shareholder rights and investigating fraud or misconduct in corporate contexts. The firm s inquiry into PepGen is based on emerging claims and could potentially uncover issues related to investor fraud, mismanag...
August 8, 2024
: This article discusses the recent financial performance and corporate developments of PepGen Inc., a clinical-stage biotechnology firm focused on oligonucleotide therapies for severe neuromuscular and neurological disorders. The recent data release from their CONNECT1 trial in Duchenne muscular dystrophy (DMD) marks a significant milestone for the company s research and development efforts. PepGen Inc. (Nasdaq: PEPG), based in Boston, is at the forefront of developing innovative oligonucleotide-based therapies intending to revolutionize the treatment landscape for severe neuromuscular and neurological conditions. Following the company s second-quarter financial results for 2024, key highlights reveal both...
January 8, 2024
As the race to find effective treatments for Duchenne Muscular Dystrophy (DMD) continues, PepGen has recently made a significant announcement that has captured the attention of medical experts and investors alike. The company has confirmed that the first patient has been dosed in the CONNECT1-EDO51 Phase 2 clinical trial of their groundbreaking drug, PGN-EDO51, targeting DMD patients who are amenable to exon 51 skipping.DMD is a devastating genetic disorder that primarily affects boys, causing progressive muscle wasting and weakness. Exon skipping therapies, like PGN-EDO51, offer hope to those affected by DMD by bypassing specific faulty sections of the dystrophin gene and allowing production of the truncate...
Inflarx N is a company that operates on a B2B (business-to-business) model. They offer a range of services and products such as software solutions, data analytics, and consulting to businesses in the technology sector. Their revenue primarily comes from subscription fees, licensing, and consulting fees.
Amicus Therapeutics Inc is a biopharmaceutical company that focuses on the development and commercialization of therapies for rare and orphan diseases.
Cytokinetics Incorporated is a biopharmaceutical company with a business model centered around the discovery and development of novel muscle activators. They strive to improve the lives of patients with debilitating diseases by focusing on the development of potentially life-changing therapies. Cytokinetics aims to achieve commercial success by leveraging its expertise in muscle biology and utilizing strategic collaborations to bring their innovative therapies to market.
Corbus Pharmaceuticals Holdings Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for inflammatory and fibrotic diseases. Their business model revolves around conducting research and clinical trials to identify potential drug candidates, obtaining regulatory approvals, and subsequently commercializing these drugs to generate revenue. They aim to address unmet medical needs by creating and marketing novel treatments for diseases such as systemic sclerosis, cystic fibrosis, and other inflammatory conditions.
Sources:
Pepgen Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Pepgen Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
